GlassScriptPhysician profile
Zhou Yu
NPI 1326300948
$958.53
in general payments reported to CMS, 2019-2025
16 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2021: $37.12 · 2022: $50.00 · 2023: $162 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376 · Education: $54.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.65 |
| Education | $54.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $175.00 | 2022-2023 | Brukinsa |
| Beone Medicines USA, INC. | $133.50 | 2025 | Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $122.45 | 2019 | |
| Tempus Ai, INC | $92.94 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $86.10 | 2019-2025 | Lynparza |
| Amgen INC. | $70.16 | 2019 | |
| Genentech USA, INC. | $58.61 | 2019 | |
| Alexion Pharmaceuticals, INC. | $41.25 | 2019-2023 | Soliris |
| Janssen Biotech, INC. | $37.12 | 2021 | |
| Pfizer INC. | $37.05 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.90 | 2019 | |
| Celgene Corporation | $18.06 | 2019 | |
| Taiho Oncology, INC. | $17.95 | 2019 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $12.59 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhou Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.